MXPA03005982A - Antagonistas de receptores de aminoacidos excitadores. - Google Patents

Antagonistas de receptores de aminoacidos excitadores.

Info

Publication number
MXPA03005982A
MXPA03005982A MXPA03005982A MXPA03005982A MXPA03005982A MX PA03005982 A MXPA03005982 A MX PA03005982A MX PA03005982 A MXPA03005982 A MX PA03005982A MX PA03005982 A MXPA03005982 A MX PA03005982A MX PA03005982 A MXPA03005982 A MX PA03005982A
Authority
MX
Mexico
Prior art keywords
amino acid
receptor antagonists
acid receptor
excitatory amino
excitatory
Prior art date
Application number
MXPA03005982A
Other languages
English (en)
Spanish (es)
Inventor
Brian Arnold Macklin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA03005982A publication Critical patent/MXPA03005982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA03005982A 2001-01-05 2001-12-19 Antagonistas de receptores de aminoacidos excitadores. MXPA03005982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01500004 2001-01-05
PCT/US2001/045857 WO2003024453A1 (en) 2001-01-05 2001-12-19 Excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA03005982A true MXPA03005982A (es) 2003-09-10

Family

ID=8183456

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005982A MXPA03005982A (es) 2001-01-05 2001-12-19 Antagonistas de receptores de aminoacidos excitadores.

Country Status (16)

Country Link
EP (2) EP1368032B1 (enExample)
JP (2) JP4132049B2 (enExample)
CN (1) CN100548299C (enExample)
AR (1) AR035219A1 (enExample)
AT (1) ATE397931T1 (enExample)
AU (1) AU2001298028B8 (enExample)
BR (1) BR0116724A (enExample)
CA (1) CA2432464C (enExample)
CY (1) CY1108259T1 (enExample)
DE (1) DE60134427D1 (enExample)
DK (1) DK1368032T3 (enExample)
ES (1) ES2306690T3 (enExample)
MX (1) MXPA03005982A (enExample)
PE (1) PE20020842A1 (enExample)
PT (1) PT1368032E (enExample)
WO (1) WO2003024453A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
MX2022015407A (es) 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
TWI924682B (zh) * 2020-07-30 2026-05-11 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
CN116332807A (zh) * 2023-03-24 2023-06-27 安徽秀朗新材料科技有限公司 一种3-(三氟甲基磺酰基)-2-萘甲酸甲酯的生产工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
TR199902449T2 (xx) * 1997-04-07 2000-07-21 Eli Lilly And Company Farmakolojik etkin maddeler.
DZ3209A1 (fr) * 1999-07-06 2001-01-11 Lilly Co Eli Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists

Also Published As

Publication number Publication date
PE20020842A1 (es) 2002-09-21
CN100548299C (zh) 2009-10-14
AU2001298028B2 (en) 2006-07-13
DK1368032T3 (da) 2008-09-29
EP1368032B1 (en) 2008-06-11
CA2432464C (en) 2011-07-19
JP4132049B2 (ja) 2008-08-13
EP2166003A1 (en) 2010-03-24
ATE397931T1 (de) 2008-07-15
JP2008179650A (ja) 2008-08-07
WO2003024453A1 (en) 2003-03-27
ES2306690T3 (es) 2008-11-16
CA2432464A1 (en) 2003-03-27
BR0116724A (pt) 2004-01-27
JP2004522804A (ja) 2004-07-29
PT1368032E (pt) 2008-09-04
AU2001298028B8 (en) 2006-08-10
DE60134427D1 (de) 2008-07-24
CN1856308A (zh) 2006-11-01
EP1368032A1 (en) 2003-12-10
AR035219A1 (es) 2004-05-05
CY1108259T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
IL165841A0 (en) Mchir antagonists
AU2002341834A1 (en) Antagonists
LT1539766T (lt) Su kalcitonino genu susijusio peptido receptoriaus antagonistai
IL158013A0 (en) Disease-associated protein
MXPA03007869A (es) Inhibidores peptidicos de desformilasa.
AP2004003156A0 (en) Peptide deformylase inhibitors.
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
PL362838A1 (en) Somatostatin antagonists
ZA956812B (en) Excitatory amino acid receptor antagonists.
PT1368032E (pt) Antagonistas de receptores dos aminoácidos excitadores
MXPA03005994A (es) Compuestos de peptidos.
PL370367A1 (en) Ccr-3 receptor antagonists v
MXPA03005981A (es) Antagonistas de receptores de aminoacidos excitatorios.
MX258179B (es) Poliamidas.
AU2002227020A1 (en) Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
HK1060350A (en) Excitatory amino acid receptor antagonists
AU2002228736A1 (en) Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
MXPA03009930A (es) Antagonistas del receptor del factor liberador de corticotropina.
AU6455501A (en) Excitatory amino acid receptor modulators
GB0128161D0 (en) Receptor protein
AU2003219955A1 (en) Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
AU2003212418A8 (en) Peptide deformylase
GB0223877D0 (en) Receptor proteins
GB0220459D0 (en) Receptor proteins
AU2002235453A1 (en) Urotensin-ii receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration